BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 18341607)

  • 21. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
    Narod SA
    Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
    Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
    Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
    Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
    J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    J Med Genet; 1999 Dec; 36(12):906-13. PubMed ID: 10593998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.
    Metcalfe KA; Esplen MJ; Goel V; Narod SA
    Psychooncology; 2004 Jan; 13(1):14-25. PubMed ID: 14745742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
    Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hereditary breast cancer: treatment and prevention].
    Ejlertsen B; Gerdes AM
    Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.
    Mislowsky A; Domchek S; Stroede C; Bergey MR; Sonnad SS; Wu L; Tchou J
    Ann Surg Oncol; 2011 Mar; 18(3):745-51. PubMed ID: 20972632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
    Metcalfe KA; Mian N; Enmore M; Poll A; Llacuachaqui M; Nanda S; Sun P; Hughes KS; Narod SA
    Breast Cancer Res Treat; 2012 Jun; 133(2):735-40. PubMed ID: 22240989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
    Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
    Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.